NCT03123588 2021-11-19Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)Incyte CorporationPhase 2 Terminated12 enrolled 15 charts